The FT Global Pharmaceutical and Biotechnology Conference is the benchmark event for the industry, attended by senior industry executives and financial professionals from around the world.
Celebrating its 38th year, the conference will focus a critical eye on the forces set to transform the industry in the years ahead.
Disruption and transformation will continue to be the focus of life science leaders in 2019 and beyond.
Pricing pressures in the US and a growing number of markets globally have already set in motion a search for new and innovative payment models, while the rise of ultra-expensive, potentially curative gene and cell therapies has brought to the fore a heated discussion about the sustainability of the industry’s underlying economic and funding model.
With a host of ‘new entrants’ in the shape of big-tech and consumer-centric start-ups nibbling at pharma’s heels in the emerging prevention and wellness space, meanwhile, pharma faces competition on an increasing number of fronts. Success in the new data and patient-centric world which is emerging will increasingly depend on forging relationships with patients sustained on trust and building new business models for the future.